(Adds revenue details in paragraph 6, analyst comments in paragraphs 3,7) Oct 30 (Reuters) – Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China. However, shares fell 3% premarket after Merck narrowed its revenue guidance for the full year. It now expects revenue of $64.5 billion to $65.0 billion compared with its prior forecast of $64.3 billion to $65.3 billion. J.P.Morgan analysts called the quarterly beat "modest", adding the annual forecasts were "largely re-iterated". Shares of Merck have fallen about 5% so far in 2025, as investors weigh the company's efforts to grow beyond Keytruda against broader industry headwinds, including potential U.S. drug prici

See Full Page